Login to Your Account



Pharma: Other News To Note


Thursday, October 25, 2012
• Pfizer Inc., of New York, said the European Commission gave conditional marketing authorization for Xalkori (crizotinib) for the treatment of adults with previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription